Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 11/20 | 0.54 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.54 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.54 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.54 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.48 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 3/20 | 0.45 |
| ▸ | CCR9 | P51686 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20249111 | 0.93 | S1PR5 (0.51) | S1PR5S1PR1S1PR4S1PR3KMT2A | |
| SCHEMBL20249113 | 0.84 | ALDH1A1 (0.53) | KMT2ALTA4H | |
| SCHEMBL18291640 | 0.84 | S1PR5 (0.57) | S1PR5S1PR1S1PR4S1PR3CD274 | |
| SCHEMBL20249418 | 0.82 | ALDH1A1 (0.47) | CD274PDCD1KMT2ALTA4H | |
| SCHEMBL20249158 | 0.82 | ALDH1A1 (0.47) | CD274PDCD1KMT2ALTA4H | |
| SCHEMBL20255310 | 0.82 | LTA4H (0.48) | KMT2ALTA4H | |
| SCHEMBL20255437 | 0.81 | S1PR5 (0.54) | S1PR5S1PR1S1PR4S1PR3CD274 | |
| SCHEMBL20037434 | 0.81 | S1PR5 (0.54) | S1PR5S1PR1S1PR4S1PR3CD274 | |
| SCHEMBL20249161 | 0.81 | HRH3 (0.45) | KMT2ALTA4HCCR9 | |
| SCHEMBL15942972 | 0.81 | S1PR5 (0.63) | S1PR5S1PR1S1PR4S1PR3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | S1PR5 2141/4885S1PR1 2509/4885S1PR4 2204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.